Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...

The International Council for Harmonisation (ICH) released a widely anticipated timetable detailing its plans to issue general guidance on model-informed drug development (MIDD) approaches in drug ...

More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise Simulations Plus, Inc. (Nasdaq: SLP) ( ...

Details on the US Food and Drug Administration’s (FDA) plans for launching a pilot project on model-informed drug development (MIDD) began trickling out on Monday with a Federal Register notice.

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being and SDG 12: Responsible Consumption & Production ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...

This figure clearly combs through the key developmental milestones of organoid technology from 2009 to 2023 in the form of a timeline, and systematically presents the breakthrough achievements of ...